Health-care company Sanofi-Aventis has announced its diabetes drug Toujeo is now commercially available in pharmacies nationwide.
“Toujeo is now on-stock in major drugstores, and Sanofi is completing its availability to other minor drugstores and hospitals in the country,” the pharma giant said in a media briefing with Sanofi reps and diabetes educators on Toujeo in January. Prescription Toujeo is a once-daily basal insulin based on a broadly used molecule (insulin glargine) injection used to control blood sugar in adults with diabetes mellitus. It contains three times as much insulin in 1 ml as standard insulin (100 units/ml) and Sanofi’s own first-generation and long-established Lantus (rDNA origin).
Lantus was first made commercially available in the US in 2002, and it is a basal insulin that addresses fasting plasma glucose and treats Type 1 and Type 2 diabetes. To date, it is the most prescribed insulin in the US.